LDR’s IPO Bid, FDA Approvals Give Spine Much Needed Adjustment
This article was originally published in The Gray Sheet
Executive Summary
The spine device firm LDR filed to raise up to $69 million in an initial public offering just as it gained FDA approval for its Mobi-C cervical disc for one- and two-level indications. Device investors will keep a close watch on the IPO, which has not been staged by a venture-backed spine startup since 2007.
You may also be interested in...
Cervical Disc Replacement Data Looks Good, But More Needed
Long-term positive outcomes for artificial cervical discs were reported, but the market remains muted by insurance restrictions, and even more data may be needed for a breakthrough.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.